In Vivo Significance of In Vitro Studies on G-Protein-Coupled Receptor Heteromers

Takato Hiranita*
Division of Neurotoxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, 3900 NCTR Road, Jefferson AR 72079-9501, USA

Interactions between distinct receptor proteins have been assessed in vitro and in vivo. Among these studies are G-Protein-Coupled Receptor (GPCR) heteromers. GPCR heteromers form a popular area for study in molecular pharmacology and are expected to contribute valuable information to clinical needs for development of medications discovery in various neuropsychiatric diseases and symptoms. For example, physical formation of GPCR heteromers could result in a novel signaling mechanism that is distinct from those of individual GPCR monomers or their homomer. However, significance of various studies on dopamine (DA) D₁/D₂ receptor heteromers was challenged by a recent report [1]. Javitch et al. [1] provided compelling evidence against D₁/D₂ heteromers, one of the most prominent subjects of interest in neuropsychiatry field.

In the study Javitch et al. performed an "in vivo" assessment of the first demonstration for the presence of DA D₁/D₂ receptor heteromers in animal tissues [1]. Surprisingly, despite the successful creation of DA D₁/D₂ receptor heteromers "in vitro", their immunohistochemical studies discovered the virtual absence of physical DA D₁/D₂ receptor heteromers in the shell region of the nucleus accumbens (NAS) from C57Bl/6J mouse brain [1]. In the NAS, DA D₁ and D₂ receptors seem to co-express in the same neuron for some neurons but did not localize [1]. The virtual absence of physical DA D₁/D₂ receptor heteromers "in vivo" was further substantiated by the discovery of lack of localization across species. For example, there was little if any signal indicative of the presence of DA D₁/D₂ receptor heteromers in the NAS from a rat and the ventral striatum from rhesus monkey. Since various drugs abused by humans are known to increase extracellular DA levels in the NAS, the "in vivo" negative results against the presence of DA D₁/D₂ receptor heteromers in the NAS could have a substantial impact at least on research for drug abuse.

In sum, the failure to demonstrate in vivo the presence of DA D₁/D₂ receptor heteromers [1] undoubtly suggests reconsideration of the use of the "in vitro preclinical" models using receptor couplings. There is a clear need to reassess the validity of this approach for the development of medications discovery regarding various neuropsychiatric diseases and symptoms.

Acknowledgments
The present work was supported by Division of Neurotoxicology/ NCTR/ U.S. FDA. The information in the present article is not a formal dissemination of information by the FDA and does not represent agency position or policy.

References